Compare Herbalife Nutrition Ltd (HLF) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs GeneDx Holdings Corp — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and GeneDx Holdings Corp for 19 Days on average.
| HLF | WGS | |
|---|---|---|
Market Cap | $1.34B | $2.02B |
Volume | 1,589,457 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $167.51 |
52-Week Low | $7.75 | $34.51 |
Typical Hold Time | 43 Days | 19 Days |
Enterprise Value | $3.18B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $13.03, up 3.0% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 8.22 and P/S of 0.26, while maintaining strong gross margins of 77.7%. Recent Q1 2026 earnings beat expectations, though Q2 2026 missed. The company announced a $250 million share repurchase program and CEO transition, with management reaffirming 2026 guidance. Cash flow trends show improvement with projected positive net cash flow of $50 million for 2026.
HLF presents a value opportunity with discounted valuation and improving debt profile, though execution risks remain. Analyst consensus targets $19.00 (53.8% upside) with 14 buy ratings. Key risks include mixed earnings performance, high debt levels despite recent reduction, and leadership transition. The stock offers potential for re-rating if management delivers on margin expansion and growth targets outlined in recent investor presentations.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
